The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Newcastle have a golden opportunity to continue their momentum with a trip to 19th-placed Leicester City tonight. The lads ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Telix Pharmaceuticals is leveraging its success with Illuccix to build a diversified theranostic platform, driving long-term ...

Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Novartis (NVS) to CHF 115 from CHF 110 and keeps a Buy rating on the ...

On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate cancer pre-chemotherapy. Just six days ...